Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease-Reference-Cited by-同舟云学术

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

Published:2018-10-01 Issue:10 Volume:75 Page:1206
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Jankovic Joseph¹,Goodman Ira²,Safirstein Beth³,Marmon Tonya K.⁴,Schenk Dale B.⁴,Koller Martin⁴,Zago Wagner⁴,Ness Daniel K.⁴,Griffith Sue G.⁵,Grundman Michael⁶⁷,Soto Jay⁴,Ostrowitzki Susanne⁸,Boess Frank G.⁹,Martin-Facklam Meret⁹,Quinn Joseph F.¹⁰¹¹,Isaacson Stuart H.¹²,Omidvar Omid¹³,Ellenbogen Aaron¹⁴,Kinney Gene G.⁴

Affiliation:

1. Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas

2. BioClinica, Orlando, Florida

3. MD Clinical, Hallandale Beach, Florida

4. Prothena Biosciences Inc, South San Francisco, California

5. ClinPharma Resources, San Diego, California

6. University of California, San Diego

7. Global R&D Partners, LLC, San Diego, California

8. Genentech Inc, Product Development, Neuroscience, South San Francisco, California

9. F. Hoffmann-La Roche Ltd, Basel, Switzerland

10. Oregon Health & Science University, Portland

11. Portland Veterans Affairs Medical Center, Portland, Oregon